This story has been updated from a previous version.
NEW YORK, March 22 - Amersham Pharmacia Biotech said Thursday it will supply its Ettan integrated proteomics technologies to the Georgia Research Alliance (GRA), a state-financed initiative to provide cutting-edge research technology to scientists in Georgia.
The proteomics equipment integrates a broad range of proteomics technologies, said Amersham spokeswoman Tracy Cheung, including 2-D electrophoresis for protein separation, spotting technology for isolating proteins, and mass spectrometry technology.
Researchers affiliated with the GRA will also have early access to Amersham's fluorescence 2-D differential in gel electrophoresis technology, which allows researchers to directly compare three different proteins on the same gel, and accompanying software for data analysis.
"We were impressed with the technology they had, and their willingness to work with us on the leading edge of their technology," said Clifton Baile, an agricultural biologist who is coordinating the GRA's collaboration with Amersham.
To allow researchers from across the state access to the technology, the GRA will install the equipment in several "core laboratories," at the Medical College of Georgia in Augusta, the University of Georgia in Athens, and Emory University in Atlanta.
The facilities will focus on providing access to the technology for academic researchers and startups associated with universities, said Baile, but essentially the equipment was available to all scientists in the state.
Cheung said financial details of the arrangement were not disclosed and that the agreement with GRA would continue indefinitely.
Amersham has several other proteomics partnerships with research labs in the UK and pharmaceutical and biotech companies, Cheung said.
The GRA, with an annual budget of about $34 million, is an 11 year-old partnership of universities, businesses, and the state government, designed to boost technology-driven business development in the state.